S&P 500   3,207.20 (-0.60%)
DOW   26,726.94 (-0.53%)
QQQ   256.89 (-1.54%)
AAPL   383.99 (-1.77%)
MSFT   203.39 (-2.24%)
FB   238.20 (-0.87%)
GOOGL   1,498.79 (-1.19%)
AMZN   2,957.05 (-1.72%)
NVDA   402.50 (-1.61%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.96 (-1.09%)
GE   7.11 (-0.42%)
TSLA   1,495.12 (-3.29%)
AMD   54.28 (-1.92%)
T   30.24 (+0.77%)
ACB   12.20 (-5.21%)
F   6.80 (+0.89%)
GILD   76.08 (-0.74%)
DIS   119.12 (-1.47%)
NFLX   517.96 (-1.01%)
BAC   24.02 (-2.36%)
BA   181.26 (-3.55%)
S&P 500   3,207.20 (-0.60%)
DOW   26,726.94 (-0.53%)
QQQ   256.89 (-1.54%)
AAPL   383.99 (-1.77%)
MSFT   203.39 (-2.24%)
FB   238.20 (-0.87%)
GOOGL   1,498.79 (-1.19%)
AMZN   2,957.05 (-1.72%)
NVDA   402.50 (-1.61%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.96 (-1.09%)
GE   7.11 (-0.42%)
TSLA   1,495.12 (-3.29%)
AMD   54.28 (-1.92%)
T   30.24 (+0.77%)
ACB   12.20 (-5.21%)
F   6.80 (+0.89%)
GILD   76.08 (-0.74%)
DIS   119.12 (-1.47%)
NFLX   517.96 (-1.01%)
BAC   24.02 (-2.36%)
BA   181.26 (-3.55%)
S&P 500   3,207.20 (-0.60%)
DOW   26,726.94 (-0.53%)
QQQ   256.89 (-1.54%)
AAPL   383.99 (-1.77%)
MSFT   203.39 (-2.24%)
FB   238.20 (-0.87%)
GOOGL   1,498.79 (-1.19%)
AMZN   2,957.05 (-1.72%)
NVDA   402.50 (-1.61%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.96 (-1.09%)
GE   7.11 (-0.42%)
TSLA   1,495.12 (-3.29%)
AMD   54.28 (-1.92%)
T   30.24 (+0.77%)
ACB   12.20 (-5.21%)
F   6.80 (+0.89%)
GILD   76.08 (-0.74%)
DIS   119.12 (-1.47%)
NFLX   517.96 (-1.01%)
BAC   24.02 (-2.36%)
BA   181.26 (-3.55%)
S&P 500   3,207.20 (-0.60%)
DOW   26,726.94 (-0.53%)
QQQ   256.89 (-1.54%)
AAPL   383.99 (-1.77%)
MSFT   203.39 (-2.24%)
FB   238.20 (-0.87%)
GOOGL   1,498.79 (-1.19%)
AMZN   2,957.05 (-1.72%)
NVDA   402.50 (-1.61%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.96 (-1.09%)
GE   7.11 (-0.42%)
TSLA   1,495.12 (-3.29%)
AMD   54.28 (-1.92%)
T   30.24 (+0.77%)
ACB   12.20 (-5.21%)
F   6.80 (+0.89%)
GILD   76.08 (-0.74%)
DIS   119.12 (-1.47%)
NFLX   517.96 (-1.01%)
BAC   24.02 (-2.36%)
BA   181.26 (-3.55%)
Log in

NASDAQ:MTEMMolecular Templates Stock Price, Forecast & News

$12.08
-0.60 (-4.73 %)
(As of 07/16/2020 12:44 PM ET)
Add
Compare
Today's Range
$11.86
Now: $12.08
$12.39
50-Day Range
$12.14
MA: $14.45
$16.15
52-Week Range
$4.51
Now: $12.08
$19.12
Volume13,905 shs
Average Volume421,779 shs
Market Capitalization$552.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Read More
Molecular Templates logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MTEM
CUSIP88580720
Phone512-869-1555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.27 million
Book Value$2.79 per share

Profitability

Net Income$-69,420,000.00
Net Margins-439.48%

Miscellaneous

Employees68
Market Cap$552.42 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

How has Molecular Templates' stock been impacted by COVID-19 (Coronavirus)?

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MTEM stock has decreased by 8.6% and is now trading at $12.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Molecular Templates?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Molecular Templates.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Molecular Templates.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) posted its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.18. The biotechnology company earned $4.14 million during the quarter, compared to analysts' expectations of $10.48 million. Molecular Templates had a negative return on equity of 76.76% and a negative net margin of 439.48%. View Molecular Templates' earnings history.

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates's stock reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

4 brokers have issued 1 year price targets for Molecular Templates' shares. Their forecasts range from $19.00 to $22.00. On average, they anticipate Molecular Templates' share price to reach $21.00 in the next year. This suggests a possible upside of 73.8% from the stock's current price. View analysts' price targets for Molecular Templates.

Has Molecular Templates been receiving favorable news coverage?

News stories about MTEM stock have been trending positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Molecular Templates earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news about Molecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,200,000 shares, a decrease of 8.4% from the May 31st total of 1,310,000 shares. Based on an average daily volume of 298,500 shares, the short-interest ratio is presently 4.0 days. Approximately 4.0% of the shares of the company are short sold. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), CEL-SCI (CVM), SLS International (SLS), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $12.08.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $552.42 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.